Compliance Radar
Who was sanctioned, and for what?
Fines, court rulings and incidents from Europe and North America: 718 cases from 32 jurisdictions, each with an official source and checked against that source before publication. Filter by country, area of law and sector. Click a chart to drill down one level.
Chemicals and pharmaceuticalsCaroline J. Campbell (Beschäftigte der ImmunityBio, Inc.)
Clear all filters
0cases from 0 jurisdictions
—Total of monetary amounts
—Largest single case
—Median per case with an amount
Click a bar to drill down one level.
Where?
by regionAll jurisdictions
No cases for this selection.
What for?
by area of lawAll areas of law
No cases for this selection.
Who?
by company- Purdue Pharma L.P. €4.75bn 87 % · 1 case
- Teva Pharmaceutical Industries (Teva-Gruppe) €462.6m 8 % · 1 case
- Gilead Sciences, Inc. €177.8m 3 % · 1 case
- Dompé U.S. Inc. €27.5m 1 % · 1 case
- SCG Plastics Co., Ltd. €18.8m 0 % · 1 case
- Alkaloids of Australia, Alkaloids Corporation, Boehringer, Linnea, Transo-Pharm (C2 PHARMA Kronzeuge) €13.4m 0 % · 1 case
- Takeda Pharmaceuticals U.S.A., Inc. €11.7m 0 % · 1 case
- Johnson & Johnson Consumer NV; Boehringer Ingelheim SComm; Haleon Belgium NV €11.2m 0 % · 1 case
- Industrial Chemicals Limited €4.37m 0 % · 1 case
- EyePoint Pharmaceuticals, Inc. €4.08m 0 % · 1 case
- 13 more€8.57m
When?
per quarter, by date of decision| Period | Cases | Total |
|---|---|---|
| Q3 2023 | 0 | — |
| Q4 2023 | 0 | — |
| Q1 2024 | 0 | — |
| Q2 2024 | 0 | — |
| Q3 2024 | 0 | — |
| Q4 2024 | 0 | — |
| Q1 2025 | 0 | — |
| Q2 2025 | 0 | — |
| Q3 2025 | 0 | — |
| Q4 2025 | 0 | — |
| Q1 2026 | 0 | — |
| Q2 2026 | 0 | — |
| Q3 2026 | 0 | — |
0 cases
No cases for this selection. Remove a filter or choose a longer period.